Semaglutide medications like Ozempic and Wegovy can help lower the risk of heart and metabolic diseases in people with schizophrenia spectrum disorders, according to a study published in JAMA Psychiatry.
Glucagon-like peptide–1 receptor agonist (GLP-1RAs) drugs, such as semaglutide, mimic the natural gut hormone GLP-1 that regulates hunger and food intake. By activating GLP-1 receptors in the brain, the drug reduces hunger and slows gastric emptying, helping one feel full longer. It also enhances glucose-dependent insulin secretion, thereby improving blood sugar control.
Researchers in Denmark recruited 73 adults taking antipsychotic medications who were showing early signs of diabetes and had an average BMI of 36, which falls in the category of obesity. The participants, aged 18 to 65 years, were randomly assigned to receive either weekly semaglutide injections or a placebo for 6.5 months.









